CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
  • About
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

Clinically Media's Ceo Named One Of The Most Influential People In Healthcare Today

Clinically Media's Ceo Named One Of...

How to Use Clinical Trial Matching Software for The Trials?

How to Use Clinical Trial Matching...

Advanced HPV-16 Positive Head and Neck Cancer: PDS Biotech Enlists First Stage of Checkpoint Inhibitor Nave Patients

Advanced HPV-16 Positive Head and...

StudyKIK Acquired by Syneos Health to Deliver Patient and Physician Benefits

StudyKIK Acquired by Syneos Health to...

Syneos Health Partners with Ride Health

Syneos Health Partners with Ride Health

How Patient Recruitment Technologies Can Enhance Clinical Trials

How Patient Recruitment Technologies...

Patient Recruitment: Market and Strategies

Patient Recruitment: Market and...

How Digital Transformation Has Impacted Patient Recruiting and Engagement Initiatives

How Digital Transformation Has...

Clinically Media's Ceo Named One Of The Most Influential People In Healthcare Today

Clinically Media's Ceo Named One Of...

How to Use Clinical Trial Matching Software for The Trials?

How to Use Clinical Trial Matching...

Advanced HPV-16 Positive Head and Neck Cancer: PDS Biotech Enlists First Stage of Checkpoint Inhibitor Nave Patients

Advanced HPV-16 Positive Head and...

StudyKIK Acquired by Syneos Health to Deliver Patient and Physician Benefits

StudyKIK Acquired by Syneos Health to...

Syneos Health Partners with Ride Health

Syneos Health Partners with Ride Health

How Patient Recruitment Technologies Can Enhance Clinical Trials

How Patient Recruitment Technologies...

Patient Recruitment: Market and Strategies

Patient Recruitment: Market and...

How Digital Transformation Has Impacted Patient Recruiting and Engagement Initiatives

How Digital Transformation Has...

Why it is Necessary to Accelerate the Clinical Trial Patient Recruitment Process

Life Sciences Review | Wednesday, July 21, 2021
Tweet

Clinical trial patient recruitment can be difficult, but it is essential to accelerate the process so that new medicines can enter the market as soon as possible. 


FREMONT, CA: One of the most challenging aspects of medical research nowadays is the speed as patients need new therapies immediately once, yet clinical studies are frequently delayed or shut down owing to a lack of individuals willing to participate.


Sponsors can meet and beat deadlines by recruiting patients for clinical trials and quickly bring novel treatments to patients. Patients worldwide seek medicines that will be better than their present options and cure their health conditions.


If the patient recruitment process for clinical trials is faster, the entire drug development process can also be done quickly. For example, a new medicine takes typically at least ten years to reach the market, with clinical trials accounting for more than half of that period (six to seven years). When that period is shortened, much-needed medicines can reach patients sooner.


It can be difficult to envision the benefits of increasing patient recruitment in a setting where even achieving stated deadlines would be a welcome shift. Here are some of the most compelling reasons to focus on accelerating patient recruiting


Save on operational cost


Running a clinical trial is a vast, enormous investment, and patient recruitment is a challenge in itself. But once patients are enrolled in a study, many people and resources are engaged in guaranteeing that the survey has appropriate sites, that the investigational medication is administered correctly, the patients are immediately 


followed, and the data is securely collected. It is also necessary to ensure all procedures are followed in producing and presenting an NDA to the FDA.


Improve sponsor's reputation


Trial sponsors are frequently required to report their medical study status to boards, investors, or shareholders. One method to ensure that the sponsor maintains support for the trial and even improves their reputation in front of the key stakeholders is to speed up recruiting and enrolment.


Move on more quickly


People know that clinical studies don't always result in a successful treatment. According to a survey, the average chance of FDA approval from Phase 1 was 9.6 percent, or one in ten, and this percentage is much lower in particularly complex diseases like cancer.


Once treatment has progressed to Phase 2, the chances of advancing to Phase 3 remain low, with less than a third of investigational treatments moving to this stage. This is the nature of clinical trials, but the difficulty is that finding patients for the trials might take years and determining that an investigational treatment doesn't work as expected can take even longer.


See Also: Top 10 Data Center Consulting/Implementation Services Companies In APAC - 2020


Weekly Brief

loading
> <
  • DNA Sequencing 2022

    Top Vendors

    Current Issue
  • BioTech Startups 2022

    Top Vendors

    Current Issue
  • DNA Sequencing 2022

    Top Vendors

    Current Issue
  • BioTech Startups 2022

    Top Vendors

    Current Issue

Read Also

Role of Predictive Genomics in Sustainable Healthcare

Role of Predictive Genomics in Sustainable Healthcare

A Conversational AI Approach to Regulatory Intelligence

A Conversational AI Approach to Regulatory Intelligence

A rise in DNA Sequencing Market is expected in coming years

A rise in DNA Sequencing Market is expected in coming years

Omniabio Inc. Announces Private Investor

Omniabio Inc. Announces Private Investor
Data analysis for next-generation sequencing worth USD1.2 billion by 2026 - Cloud-based platforms emerging as preferred solutions

Data analysis for next-generation sequencing worth USD1.2 billion by 2026 - Cloud-based platforms emerging as preferred solutions

Lithuania's Vision to Become a Biotech Hub in Europe

Lithuania's Vision to Become a Biotech Hub in Europe

Bridging the Diversity Gap in Genomics

Bridging the Diversity Gap in Genomics

How does Biotechnology Provide Solutions to Human Needs?

How does Biotechnology Provide Solutions to Human Needs?
Loading...

Copyright © 2022 Life Science Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/why-it-is-necessary-to-accelerate-the-clinical-trial-patient-recruitment-process--nwid-394.html